General
Preferred name
ATAZANAVIR
Synonyms
BMS-232632 sulfate ()
Zrivada ()
Reyataz ()
Latazanavir ()
BMS-232632 ()
ATAZANAVIR SULFATE ()
Compound 120 ()
Atazanavir (sulfate) ()
BMS-232632-05, Reyataz ()
Latazanavir, Zrivada, Reyataz, BMS-232632 ()
Atazanavir (BMS-232632) Sulfate ()
NSC-742546 ()
BMS-232632-05 ()
Atazanavir so4 ()
Atazanavir mylan ()
Atazor ()
Atazanavir viatris (previously atazanavir mylan) ()
Atazanavir (as sulfate) ()
Atazanaviri sulfas ()
Atazanavir sulphate ()
Atazanavir sulfate component of evotaz ()
Atazanavir krka ()
CGP-73547 ()
Atazanavir-d6 ()
P&D ID
PD009825
CAS
198904-31-3
229975-97-7
1092540-56-1
1092540-50-5
Tags
available
drug
Approved by
FDA
EMA
First approval
2003
Drug indication
HIV infection
Human immunodeficiency virus infection
HIV-1 infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 ¦ÌM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death[1][2][3][4][5][6][7][8].
PRICE 68
DESCPRITION An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.
DESCRIPTION Atazanavir is a human immunodeficiency virus 1 (HIV-1) protease inhibitor (PI) . (GtoPdb)
DESCRIPTION Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 ¦ÌM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death[1][2][3][4][5][6][7][8].
PRICE 68
DESCRIPTION Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM. It is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus. (BOC Sciences Bioactive Compounds)
DESCRIPTION Atazanavir sulfate (BMS-232632 sulfate) is an azapeptide and HIV-protease inhibitor used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents. (TargetMol Bioactive Compound Library)
DESCRIPTION Atazanavir is an antiviral protease inhibitor used in combination with other antiretrovirals for the treatment of HIV. (Enamine Bioactive Compounds)
DESCRIPTION Atazanavir (BMS-232632)(BMS-232632) is an highly effective HIV-1 protease inhibitor. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
8
Compound Sets
24
AdooQ Bioactive Compound Library
A10096
A10097
Axon Medchem Screening Library
1753
BOC Sciences Bioactive Compounds
atazanavir-sulfate-cas-229975-97-7-item-84-63467
Cayman Chemical Bioactives
11733
26456
ChEMBL Approved Drugs
CHEMBL1200678
CHEMBL1163
ChEMBL Drugs
CHEMBL1200678
CHEMBL1163
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01072
DrugBank Approved Drugs
DB01072
DrugCentral
254
DrugCentral Approved Drugs
254
DrugMAP
DMSYRBX
DrugMAP Approved Drugs
DMSYRBX
Enamine Bioactive Compounds
EBC-13816
EU-OPENSCREEN Bioactive Compound Library
EOS100119
Guide to Pharmacology
11138
MedChem Express Bioactive Compound Library
HY-17367A
HY-17367
NCATS Inxight Approved Drugs
QZU4H47A3S
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
Atazanavir
atazanavir-reyataz
TargetMol Bioactive Compound Library
T0100
T0100L
The Spectrum Collection
External IDs
75
Properties
(calculated by RDKit )
Molecular Weight
704.39
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
5
Rotatable Bonds
14
Ring Count
3
Aromatic Ring Count
3
cLogP
4.21
TPSA
171.22
Fraction CSP3
0.45
Chiral centers
4.0
Largest ring
6.0
QED
0.15
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Cytochrome P450
HIV
HIV Protease
P-gp (P-glycoprotein)
SARS-CoV
Protease inhibitor
Endogenous Metabolite
P-glycoprotein
Toll-like Receptor (TLR)
HIV Protease,P450 (e.g. CYP17),P-gp
Indication
human immunodeficiency virus (HIV-1)
MOA
HIV Protease inhibitor
Pathway
Membrane Transporter/Ion Channel
Metabolism
Microbiology/virology
Neuroscience
Proteases/Proteasome
Anti-infection
Immunology/Inflammation
Metabolic Enzyme/Protease
Therapeutic Class
Anti-HIV Agents
Solubility
In Vitro:<br/>DMSO : 166 mg/mL(206.74 mM
Need ultrasonic and warming)<br/>H2O : < 0.1 mg/mL(insoluble)<br/>In Vivo:<br/>1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline<br/>Solubility: ≥ 2.5 mg/mL (3.11 mM)
Clear solution<br/>2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline)<br/>Solubility: ≥ 2.5 mg/mL (3.11 mM)
Clear solution<br/>3.Add each solvent one by one:10% DMSO >> 90%corn oil<br/>Solubility: ≥ 2.5 mg/mL (3.11 mM)
Clear solution<br/>4.Add each solvent one by one:5% DMSO >> 40%PEG300 >> 5%Tween-80 >> 50% saline<br/>Solubility: ≥ 2.5 mg/mL (3.11 mM)
Clear solution<br/>5.Add each solvent one by one:5% DMSO >> 95% (20%SBE-β-CDin saline)<br/>Solubility: ≥ 2.5 mg/mL (3.11 mM)
Clear solution
Source data